Olivier Sitbon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3325579/publications.pdf

Version: 2024-02-01

356 papers	35,753 citations	4388 86 h-index	3579 181 g-index
377 all docs	377 docs citations	377 times ranked	13290 citing authors

#	Article	IF	Citations
1	Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1023-1030.	5.6	1,736
2	Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2004, 351, 1425-1436.	27.0	1,627
3	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	27.0	1,626
4	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet, The, 2001, 358, 1119-1123.	13.7	1,421
5	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 40, 780-788.	2.8	1,290
6	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264
7	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	27.0	1,168
8	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040
9	Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S40-S47.	2.8	819
10	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	27.0	790
11	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	2.8	584
12	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 36, 549-555.	6.7	582
13	Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2008, 149, 521.	3.9	558
14	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
15	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	6.7	527
16	Severe Pulmonary Hypertension during Pregnancy. Anesthesiology, 2005, 102, 1133-1137.	2.5	483
17	Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S78-S84.	2.8	463
18	Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 108-113.	5.6	402

#	Article	IF	Citations
19	Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	2.5	368
20	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nature Genetics, 2014, 46, 65-69.	21.4	351
21	Immunosuppressive therapy in lupusâ€•and mixed connective tissue diseaseâ€“associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
22	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697.	6.7	319
23	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest, 2006, 130, 182-189.	0.8	316
24	International Liver Transplant Society Practice Guidelines. Transplantation, 2016, 100, 1440-1452.	1.0	309
25	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
26	Prognostic Factors for Survival in Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1433-1439.	5.6	295
27	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	1.0	295
28	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longâ€term survival. Arthritis and Rheumatism, 2011, 63, 3522-3530.	6.7	291
29	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
30	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287
31	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. Circulation, 2014, 130, 2189-2208.	1.6	278
32	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	1.3	277
33	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	2.2	272
34	Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension. Chest, 2003, 124, 247-254.	0.8	271
35	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383.	5.6	269
36	Pulmonary veno-occlusive disease. European Respiratory Journal, 2009, 33, 189-200.	6.7	267

#	Article	IF	Citations
37	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 851-861.	5.6	259
38	Treatment Goals of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D73-D81.	2.8	250
39	Bosentan for the Treatment of Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1212-1217.	5.6	238
40	Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease. American Journal of Roentgenology, 2004, 183, 65-70.	2.2	234
41	Severe Pulmonary Hypertension in Histiocytosis X. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 216-223.	5.6	231
42	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
43	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	5.6	220
44	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 1898-1907.	2.2	218
45	Criteria for diagnosis of exercise pulmonary hypertension. European Respiratory Journal, 2015, 46, 728-737.	6.7	213
46	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S97-S107.	2.8	209
47	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	8.2	208
48	Prostanoid therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S56-S61.	2.8	184
49	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095.	6.7	173
50	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
51	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
52	PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 451-458.	2.1	153
53	Endothelin receptor antagonists in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S62-S67.	2.8	153
54	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75.	2.2	149

#	Article	IF	Citations
55	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
56	Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908.	6.7	142
57	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases, 2013, 72, 1940-1946.	0.9	128
58	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.6	126
59	Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology, 2011, 8, 526-538.	13.7	125
60	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	6.7	124
61	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	10.7	123
62	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
63	Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. European Respiratory Journal, 2010, 35, 1294-1302.	6.7	119
64	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine,the, 2019, 7, 594-604.	10.7	119
65	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219.	0.8	117
66	RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 459-475.	2.1	116
67	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 915-917.	6.7	111
68	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700465.	6.7	111
69	Systemic sclerosisâ€“related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464.	6.7	109
70	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis and Rheumatism, 2012, 64, 2995-3005.	6.7	108
71	Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 6-30.	5.4	104
72	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103

#	Article	IF	Citations
73	Pathways in pulmonary arterial hypertension: the future is here. European Respiratory Review, 2012, 21, 321-327.	7.1	100
74	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	10.7	99
75	Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives. Chest, 1998, 114, 195S-199S.	0.8	97
76	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	6.7	97
77	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy, 2009, 26, 813-825.	2.9	96
78	Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension. Circulation, 1996, 93, 484-488.	1.6	96
79	Pulmonary Artery Pressureâ€“Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 338-340.	5.6	94
80	Pulmonary veno-occlusive disease: Recent progress and current challenges. Respiratory Medicine, 2010, 104, S23-S32.	2.9	94
81	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	5.6	94
82	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	6.7	92
83	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500.	1.9	91
84	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158.	0.6	91
85	Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal, 2013, 41, 578-587.	6.7	91
86	Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1493-1499.	5.6	90
87	Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. European Respiratory Journal, 2009, 34, 1348-1356.	6.7	90
88	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal, 2020, 56, 2001875.	6.7	90
89	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2021, 78, 1393-1403.	2.8	90
90	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	6.7	89

#	Article	IF	Citations
91	Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax, 1999, 54, 273-277.	5.6	88
92	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	6.7	87
93	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	6.7	83
94	Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164.	6.7	82
95	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	2.8	82
96	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respiratory Research, 2010, 11, 73.	3.6	81
97	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634.	6.7	80
98	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80
99	Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure. Radiology, 2002, 222, 782-788.	7.3	79
100	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	3.7	78
101	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	1.9	77
102	Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172.	6.7	75
103	Epoprostenol and pulmonary arterial hypertension: 20â€…years of clinical experience. European Respiratory Review, 2017, 26, 160055.	7.1	70
104	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	2.2	69
105	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68
106	Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	7.3	68
107	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.8	68
108	The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. European Respiratory Journal, 2015, 46, 879-882.	6.7	67

#	Article	IF	Citations
109	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
110	Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension. Circulation, 2000, 102, 2460-2462.	1.6	65
111	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	2.2	65
112	Pulmonary vascular abnormalities in cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 141-159.	2.4	64
113	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493.	0.8	63
114	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211.	1.0	60
115	Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension. European Respiratory Journal, 2014, 44, 704-713.	6.7	60
116	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	6.7	60
117	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217.	2.7	59
118	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842.	0.6	57
119	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361.	0.8	55
120	Primary pulmonary hypertension: Current therapy. Progress in Cardiovascular Diseases, 2002, 45, 115-128.	3.1	54
121	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology, 2010, 49, 940-944.	1.9	53
122	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83.	6.7	53
123	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 408-417.	7.1	53
124	Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats. Circulation, 2010, 122, 1937-1947.	1.6	51
125	Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8.	4.1	51
126	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.8	50

#	Article	IF	Citations
127	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
128	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	6.7	50
129	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	7.1	48
130	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	2.5	47
131	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. European Respiratory Journal, 2005, 26, 969-972.	6.7	46
132	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest, 2010, 137, 1297-1303.	0.8	46
133	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	1.0	46
134	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.8	46
135	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 860-868.	5.6	45
136	Hemodynamics in Pulmonary Arterial Hypertension: Current and Future Perspectives. American Journal of Cardiology, 2012, 110, S9-S15.	1.6	44
137	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	6.7	44
138	Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444.	6.7	44
139	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072.	6.7	43
140	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43
141	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Medicale, 2014, 43, e345-e363.	1.9	42
142	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164.	3.3	42
143	Automatic quantification of right ventricular function with gated blood pool SPECT. Journal of Nuclear Cardiology, 2004, 11, 293-304.	2.1	41
144	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. European Respiratory Journal, 2021, 58, 2100116.	6.7	41

#	Article	IF	Citations
145	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. Medicine (United States), 2016, 95, e4911.	1.0	40
146	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	7.1	40
147	Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340.	6.7	40
148	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	6.7	39
149	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.6	39
150	Systolic and Mean Pulmonary Artery Pressures. Chest, 2015, 147, 943-950.	0.8	38
151	Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 411-420.	2.1	37
152	Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 1495-1498.	6.7	37
153	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Archives of Cardiovascular Diseases, 2017, 110, 303-316.	1.6	37
154	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 1234-1242.	0.6	37
155	French recommendations for the management of systemic sclerosis. Orphanet Journal of Rare Diseases, 2021, 16, 322.	2.7	37
156	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2015, 46, 1851-1853.	6.7	35
157	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. Drug Safety, 2016, 39, 287-294.	3.2	35
158	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000673.	6.7	35
159	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111.	5.6	35
160	Gutâ€“Lung Connection in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 402-405.	2.9	34
161	Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2008, 2, 249-265.	2.6	33
162	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. Chest, 2015, 147, 1385-1394.	0.8	33

#	Article	IF	Citations
163	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	2.5	33
164	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research, 2002, 63, 227-246.	1.2	32
165	HIV-related pulmonary arterial hypertension: clinical presentation and management. Aids, 2008, 22, S55-S62.	2.2	32
166	Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. European Respiratory Review, 2009, 18, 272-290.	7.1	31
167	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. European Respiratory Journal, 2016, 48, 254-257.	6.7	31
168	Sex and gender in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 200330.	7.1	31
169	Portopulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 651-661.	2.1	30
170	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. Aids, 2005, 19, 1239-1240.	2.2	29
171	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	1.3	29
172	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	2.5	29
173	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. International Journal of Cardiology, 2014, 172, 561-567.	1.7	28
174	Interferon-induced pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 415-420.	2.6	28
175	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279.	6.7	28
176	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	6.7	28
177	Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. European Respiratory Journal, 2009, 34, 1204-1206.	6.7	27
178	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	2.2	27
179	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	5.6	27
180	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Chest, 2013, 144, 1512-1520.	0.8	26

#	Article	IF	Citations
181	Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416.	1.9	26
182	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800279.	6.7	26
183	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.8	26
184	Pulmonary veno-occlusive disease: The bÃªte noire of pulmonary hypertension in connective tissue diseases?. Presse Medicale, 2011, 40, e87-e100.	1.9	25
185	Exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Review, 2017, 26, 170039.	7.1	25
186	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	1.7	25
187	Pulmonary hypertension associated with neurofibromatosis type 1. European Respiratory Review, 2018, 27, 180053.	7.1	25
188	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. European Respiratory Journal, 2020, 55, 1802108.	6.7	24
189	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. Journal of Heart and Lung Transplantation, 2021, 40, 1009-1018.	0.6	24
190	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-7.	1.7	24
191	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
192	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 1585-1596.	1.8	23
193	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 689-697.	0.6	23
194	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
195	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205.	3.3	22
196	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <scp>GRIPHON</scp> study. European Journal of Heart Failure, 2022, 24, 205-214.	7.1	22
197	The association between resting and mild-to-moderate exercise pulmonary artery pressure. European Respiratory Journal, 2012, 39, 313-318.	6.7	21
198	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	6.7	21

#	Article	IF	Citations
199	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.8	21
200	Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial. Chest, 2012, 142, 1026A.	0.8	20
201	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. Respiration, 2013, 85, 471-477.	2.6	20
202	New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131.	1.8	20
203	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110.	0.6	20
204	Pulmonary Arterial Hypertension and HIV Infection. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 440-447.	2.1	19
205	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175.	3.8	19
206	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	5.6	19
207	Patientsâ€™, relativesâ€™, and practitionersâ€™ views of pulmonary arterial hypertension: A qualitative study. Presse Medicale, 2016, 45, e11-e27.	1.9	18
208	Risk stratification in pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2018, 24, 407-415.	2.6	18
209	Riociguat: Clinical research and evolving role in therapy. British Journal of Clinical Pharmacology, 2021, 87, 2645-2662.	2.4	18
210	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	2.6	17
211	Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. European Respiratory Journal, 2020, 55, 1902418.	6.7	17
212	Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis. Liver Transplantation, 2020, 26, 935-940.	2.4	17
213	Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 645-653.	2.1	16
214	A prospective study of the 6â€...min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ¯ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.9	16
215	Validation of a risk assessment instrument for pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4182-4185.	2.2	16
216	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Research, 2022, 8, 00479-2021.	2.6	16

#	Article	IF	Citations
217	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583.	5.6	16
218	Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1587-1598.	3.3	15
219	The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238.	7.1	15
220	Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure. Respiration, 2013, 85, 464-470.	2.6	15
221	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398.	0.6	15
222	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.6	15
223	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	6.7	15
224	An emerging phenotype of pulmonary arterial hypertension patients carryingSOX17variants. European Respiratory Journal, 2022, 60, 2200656.	6.7	15
225	Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opinion on Pharmacotherapy, 2005, 6, 1337-1348.	1.8	14
226	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207.	0.8	14
227	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. European Respiratory Journal, 2021, 58, 2004066.	6.7	14
228	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550.	6.7	13
229	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. Journal of Heart and Lung Transplantation, 2017, 36, 399-406.	0.6	13
230	Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. Chest, 2019, 155, 991-998.	0.8	13
231	Survival Improved in Patients AgedÂâ‰ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.8	13
232	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
233	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. Chest, 2016, 150, 256-258.	0.8	12
234	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541.	5.6	12

#	Article	IF	Citations
235	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	1.7	12
236	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	5.6	12
237	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	6.7	12
238	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in Therapy, 2022, 39, 796-810.	2.9	12
239	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, S74-S80.	2.9	11
240	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. European Respiratory Journal, 2014, 43, 641-643.	6.7	11
241	Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. PLoS ONE, 2015, 10, e0134221.	2.5	10
242	Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	1.7	10
243	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 647-656.	0.6	10
244	Pulmonary hypertension due to left heart disease. Archives of Cardiovascular Diseases, 2017, 110, 420-431.	1.6	10
245	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.8	10
246	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.8	10
247	Pulmonary Venoocclusive Disease and Failure of Specific Therapy. Chest, 2009, 136, 1181.	0.8	9
248	Medical Treatment of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 686-700.	2.1	9
249	Age, risk and outcomes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800629.	6.7	9
250	Management of pulmonary arterial hypertension in patients aged over 65 years. European Heart Journal Supplements, 2019, 21, K29-K36.	0.1	9
251	Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure. Chest, 2011, 140, 1066-1068.	0.8	8
252	Biomarkers for the prognosis of pulmonary arterial hypertension: Holy grail or flying circus?. Journal of Heart and Lung Transplantation, 2014, 33, 341-343.	0.6	8

#	Article	IF	Citations
253	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	2.2	8
254	Pulmonary arterial hypertension registries: past, present and into the future. European Respiratory Review, 2019, 28, 190128.	7.1	8
255	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
256	Calcium-Channel Blockers in Pulmonary Arterial Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 161-175.	1.8	8
257	Calcium-Channel Blockers in Pulmonary Arterial Hypertension. Handbook of Experimental Pharmacology, 2013, , 161-175.	1.8	8
258	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2014, 8, 84-92.	2.6	7
259	Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension. BioMed Research International, 2016, 2016, 1-8.	1.9	7
260	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. European Respiratory Review, 2016, 25, 93-96.	7.1	7
261	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. European Respiratory Journal, 2021, 58, 2100466.	6.7	7
262	Idiopathic pulmonary hypertension: what did we learn from genes?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22 Suppl 1, S91-100.	0.2	7
263	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1285-1293.	0.6	6
264	Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease. Circulation, 2012, 125, 2045-2047.	1.6	5
265	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214.	6.7	5
266	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	2.1	5
267	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. British Journal of Anaesthesia, 2020, 125, e466-e468.	3.4	5
268	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.8	5
269	Hereditary hemorrhagic telangiectasia and liver involvement. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 426-432.	1.5	5
270	The isobaric pulmonary arterial compliance in pulmonary hypertension. ERJ Open Research, 2021, 7, 00941-2020.	2.6	5

#	Article	IF	Citations
271	Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. Pulmonary Circulation, 2021, 11, 1-9.	1.7	5
272	Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. European Respiratory Journal, 2022, 60, 2200107.	6.7	5
273	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. Current Opinion in Pulmonary Medicine, 2010, 16, S21-S26.	2.6	4
274	Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment. European Respiratory Review, 2014, 23, 505-509.	7.1	4
275	Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€• Circulation, 2016, 133, e592-3.	1.6	4
276	Are indexed values better for defining exercise pulmonary hypertension?. European Respiratory Journal, 2017, 50, 1700240.	6.7	4
277	The dangerous and contradictory prognostic significance of PVR<3WU when TAPSE<16mm in postcapillary pulmonary hypertension. ESC Heart Failure, 2020, 7, 2398-2405.	3.1	4
278	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. International Journal of Clinical Pharmacy, 2020, 42, 1128-1138.	2.1	4
279	Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. Journal of Heart and Lung Transplantation, 2022, 41, 411-420.	0.6	4
280	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935.	2.6	4
281	Bosentan therapy for pulmonary arterial hypertension. Future Cardiology, 2005, 1, 299-309.	1.2	3
282	Portopulmonary Hypertension. Chest, 2012, 141, 840-842.	0.8	3
283	Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. Chest, 2013, 144, 876A.	0.8	3
284	Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). Chest, 2015, 148, 961A.	0.8	3
285	Response to Letter Regarding Article, â€œAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertensionâ€• Circulation, 2015, 132, e154.	1.6	3
286	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. International Journal of Cardiology, 2015, 184, 763-765.	1.7	3
287	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. Journal of Clinical Monitoring and Computing, 2017, 31, 903-910.	1.6	3
288	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2001047.	6.7	3

#	Article	IF	Citations
289	Portopulmonary hypertension: An unfolding story. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101492.	1.5	3
290	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. European Respiratory Journal, 2021, 57, 2003132.	6.7	3
291	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	3.8	3
292	Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12.	1.7	3
293	Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH). , 2018, , .		3
294	Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. , 2015, , .		3
295	Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 378-379.	5.6	2
296	Pulmonary Arterial Hypertension and HIV and Other Viral Infections. Progress in Respiratory Research, 2012, , 105-112.	0.1	2
297	Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal. European Respiratory Review, 2012, 21, 259-262.	7.1	2
298	Six-Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2015, 34, S160.	0.6	2
299	Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension. Respiration, 2020, 99, 678-685.	2.6	2
300	Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH). , 2018, , .		2
301	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. Pulmonary Circulation, 2022, 12, e12023.	1.7	2
302	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2022, 8, 00665-2021.	2.6	2
303	To be or not to beâ€¦ treated with initial combination therapy, that is the (PAH) question. European Respiratory Journal, 2022, 59, 2200390.	6.7	2
304	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	2.9	2
305	Impact Of Pulmonary Arterial Hypertension Specific Therapy On Portopulmonary Hypertension. , 2010, , .		1
306	Correcting For Age And Sex Unmasks Decreased Right Ventricular Ejection Fraction In Pulmonary Hypertension. , 2011, , .		1

#	Article	IF	Citations
307	The Angle Between The Interventricular Septum And The Left Ventricular Free Wall As A New Index Of Right Ventricular Overload In Pulmonary Hypertension Patients: A Cardiac Magnetic Resonance Study. , 2011, , .		1
308	Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. Chest, 2013, 144, 879A.	0.8	1
309	Outcome of Portopulmonary Hypertension After Liver Transplantation. Transplantation, 2018, 102, e190-e191.	1.0	1
310	Assembly 13: placing the pulmonary circulation in the heart of ERS. Breathe, 2019, 15, 88-89.	1.3	1
311	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e90-e91.	5.6	1
312	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La PiÃ¨ce de RÃ©sistance?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 524-525.	5.6	1
313	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. Respiratory Medicine, 2020, , 79-96.	0.1	1
314	Management of selexipag interruptions in the GRIPHON study. , 2016, , .		1
315	Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial. , 2018, , .		1
316	Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study. , 2018, , .		1
317	Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading. , 2018, , .		1
318	Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results. , 2015, , .		1
319	Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study. , 2017, , .		1
320	Effects Of HIV Protease Inhibitors On Progression Of Monocrotaline-induced Pulmonary Hypertension In Rats. , 2010, , .		0
321	Catheter Related-infections In Pulmonary Hypertension Patients Treated By Continuous Intravenous Epoprostenol: Experience Of The French Referral Centre. , 2010, , .		0
322	Clinical Characteristics And Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Diagnosed By A Systematic Detection Program. , 2011, , .		0
323	Ventilation Perfusion Lung Scan In Pulmonary Veno-Occlusive Disease. , 2011, , .		0
324	Portopulmonary Hypertension and Hepatopulmonary Syndrome. Progress in Respiratory Research, 2012, , 113-121.	0.1	0

#	Article	IF	Citations
325	Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan. Chest, 2013, 144, 870B.	0.8	0
326	Highlights from the ERS International Congress 2018: Assembly 13 â€“ Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	2.6	0
327	Reply to: â€œManagement of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?â€• Journal of Hepatology, 2021, 74, 238-239.	3.7	0
328	Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated. European Respiratory Journal, 2021, 57, 2004258.	6.7	0
329	Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , .	5.6	0
330	Pulmonary hypertension associated with portal hypertension. , 2011, , 245-250.		0
331	Pulmonary hypertension related to appetite suppressants. , 2011, , 236-244.		0
332	Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis. , 2012, , 182-193.		0
333	Effects of 12-week exercise training-related rehabilitation on exertional dyspnoea in patients with idiopathic pulmonary arterial hypertension. , 2015, , .		0
334	Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study. , 2015, , .		0
335	Characteristics and outcomes of heritable pulmonary veno-occlusive disease due toEIF2AK4mutations. , 2015, , .		0
336	Small airways dysfunction in chronic thromboembolic pulmonary hypertension. , 2015, , .		0
337	Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network. , 2015, , .		0
338	Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice. , 2015, , .		0
339	Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era. , 2015, , .		0
340	Clinical phenotypes and outcomes of pulmonary veno-occlusive disease in carriers of bi-allelicEIF2AK4mutations. , 2016, , .		0
341	Illicit drug use and pulmonary arterial hypertension: Not so frequent. , 2016, , .		0
342	Bacterial translocation in pulmonary hypertension. , 2017, , .		0

#	Article	IF	Citations
343	Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies. , 2017, , .		0
344	Outcomes of patients with precapillary pulmonary hypertension admitted to an intensive care unit for acute right heart failure. , 2017, , .		0
345	Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. , 2017, , .		0
346	Is there an obesity paradox in pulmonary arterial hypertension?. , 2017, , .		0
347	Risk categories from European guidelines applied to the French Pulmonary Hypertension (PH) registry. , 2017, , .		0
348	Prognostic value of hemodynamics following treatment initiation in pulmonary arterial hypertension. , 2017, , .		0
349	Balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). , 2018, , .		0
350	Identifying chronic thromboembolic pulmonary hypertension (CTEPH) through French national hospital database (PMSI). , 2018, , .		0
351	Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy. , 2018, , .		0
352	Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era. , 2018, , .		0
353	Efficacy and safety of tadalafil in portopulmonary hypertension. , 2018, , .		0
354	Right heart failure. , 0, , 32-47.		0
355	ERS statement on chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 13-52.	0.8	0
356	Erythrocytes are altered in pulmonary arterial hypertension. European Respiratory Journal, 0, , 2200506.	6.7	0